Psyched: MDMA On Health Canada's Radar, MindMed Seeks FDA Support For LSD, Numinus Buys Mindspace

Health Canada Considers MDMA And Psilocybin 'Special Access' Program

This week, Health Canada opened a public consultation on its “proposal to restore potential access to restricted drugs through the Special Access Program (SAP).”

The SAP allows healthcare professionals to request unapproved drugs for patients with serious or life-threatening conditions if other therapies have failed, aren’t suitable or are not available in Canada.

The proposal includes bringing MDMA and psilocybin back from a 2013 amendment to the Food and Drug Regulations that restricted these drugs, among others, to be part of the SAP.

If the once restricted drugs qualify again for the SAP, they would be treated as controlled substances, thus allowing healthcare professionals to request these drugs for patients.

The agency will be receiving public comments on the new amendment until Feb. 10.

Numinus Acquires Mindspace Wellbeing

Psychedelics Biotech company Numinus Wellness (TSXV: NUMI) announced this week the acquisition of Mindspace Wellbeing, an organization that offers ketamine-assisted psychotherapy as well as other forms of treatment at three Montreal locations.

“This is a first and major step forward in our plan for global expansion of revenue-generating clinics and virtual therapy with the objective of health and wellness for all," Numinus CEO Payton Nyquvest.

The acquisition adds a Montreal presence to Numinus’ existing Vancouver location. The deal was closed for approximately CA$3.7 million ($2.9 million).

On Thursday, the company also announced having successfully exercised its Health Canada License to extract psilocybin from naturally-produced psilocybe mushrooms.

"In the extraction process, Numinus Bioscience's goal is to optimize Psilocybe …

Full story available on Benzinga.com

More Psyched: MDMA On Health Canada's Radar, MindMed Seeks FDA Support For LSD, Numinus Buys Mindspace